Peptides Similar to 5-Amino-1MQ

Overview#

Evidence Level: Preclinical Only -- 5-Amino-1MQ has no human clinical data. Comparisons below are based on preclinical evidence and mechanistic reasoning.

5-Amino-1MQ belongs to a broader category of compounds targeting NAD+ metabolism and cellular energy balance for anti-aging and metabolic benefits. Understanding how it compares to related approaches helps contextualize its potential role and current evidence limitations.

Detailed Comparisons#

5-Amino-1MQ vs NAD+ Precursors (NMN/NR)#

This is the most relevant comparison, as all three approaches aim to increase intracellular NAD+ levels:

Key distinction: NMN and NR increase NAD+ by providing substrate -- essentially "adding fuel." 5-Amino-1MQ increases NAD+ by blocking NNMT, which would otherwise divert nicotinamide away from the NAD+ salvage pathway -- essentially "plugging a drain." These mechanisms are theoretically complementary, though no studies have evaluated them in combination.

Critical advantage of NMN/NR: Both have published human clinical trial data establishing safety, bioavailability, and NAD+ increases in humans. 5-Amino-1MQ lacks any human data.

5-Amino-1MQ vs MOTS-c#

Both compounds target metabolic dysfunction with relevance to aging:

Both compounds show promise for metabolic health and aging, but MOTS-c is further along in clinical translation.

5-Amino-1MQ vs Other NNMT Inhibitors#

5-Amino-1MQ is not the only NNMT inhibitor under investigation. Other approaches include:

• JBSNF-000088: Another small molecule NNMT inhibitor studied for muscle stem cell activation in aged tissue (PMID: 30753815). Has shown effects on satellite cell function and muscle regeneration
• Antisense oligonucleotides: Genetic approaches to reduce NNMT expression, used primarily as research tools
• Nicotinamide analogs: Other structural analogs of the NNMT substrate being developed as inhibitors

5-Amino-1MQ remains the most extensively published NNMT inhibitor in preclinical obesity and muscle aging models.

Key Contextual Points#

When evaluating 5-Amino-1MQ against alternatives:

1. Evidence hierarchy matters: Compounds with human clinical data (NMN, NR, MOTS-c) have a fundamentally stronger evidence base than those with only preclinical data
2. Complementary mechanisms: NNMT inhibition and NAD+ precursor supplementation are not mutually exclusive, though combination effects are unstudied
3. Translation uncertainty: The dramatic effects seen in mouse models (e.g., 40% grip strength improvement) may not translate to human physiology
4. Safety unknowns: Without human data, 5-Amino-1MQ's safety profile cannot be compared to compounds with established human safety records